Table 4.
In vitro anticancer effects of Lebanese D. carota ssp. carota.
| Extracts/Compounds | Detail | Concentration/Dose | References |
|---|---|---|---|
| Methanol/Acetone (1:1) Daucus carota oil extract (DCOE) | Cytotoxicty against U937 | IC50 = 1 μg/mL | [25] |
| Cytotoxicty against KG-1 | IC50 = 1 μg/mL | ||
| Cytotoxicty against HL60 | IC50 = 5.5 μg/mL | ||
| Cytotoxicty against TF1-VSrc | IC50 = 7.3 μg/mL | ||
| Cytotoxicty against Mono-Mac-6 | IC50 = 12.4 μg/mL | ||
| Cytotoxicty against Mono-Mac-1 | IC50 = 13.2 μg/mL | ||
| Cytotoxicty against TF1-VRaf | IC50 = 14.4 μg/mL | ||
| Cytotoxicty against MV-4-11 | IC50 = 14.9 μg/mL | ||
| Cytotoxicty against ML1 | IC50 = 19.6 μg/mL | ||
| Cytotoxicty against TF1-HaRas | IC50 = 26 μg/mL | ||
| Cytotoxicty against ML2 | IC50 = 26.2 μg/mL | ||
| Cytotoxicity against human peripheral blood mononuclear cells (PBMCs) | IC50 > 100 μg/mL | ||
| Cytotoxicty against HT-29 | IC50 = 34 μg/mL | [37] | |
| Cytotoxicty against MDA-MB231 | IC50 = 27 μg/mL | ||
| Cytotoxicty against MCF-7 | IC50 = 33 μg/mL | ||
| Cytotoxicty against Caco-2 | IC50 = 30 μg/mL | ||
| Pentane (100%) fraction (F1) Pentane: diethyl ether (50:50) fraction (F2) Diethyl ether (100%) fraction (F3) Chloroform: methanol (93:7) fraction (F4) |
F1: Cytotoxicty against MDA-MB-231 | IC50 = 17 μg/mL | [89] |
| Cytotoxicty against MCF-7 | IC50 = 22 μg/mL | ||
| F2: Cytotoxicty against MDA-MB-231 | IC50 = 11 μg/mL | ||
| Cytotoxicty against MCF-7 | IC50 = 32 μg/mL | ||
| F3: Cytotoxicty against MDA-MB-231 | IC50 = 27 μg/mL | ||
| Cytotoxicty against MCF-7 | IC50 = 48 μg/mL | ||
| F4: Cytotoxicty against MDA-MB-231 | IC50 = 23 μg/mL | ||
| Cytotoxicty against MCF-7 | IC50 = 43 μg/mL | ||
| F1: Cytotoxicty against HaCaT-ras A5 | IC50 = 10.6 μg/mL | [91] | |
| Cytotoxicty against HaCaT-ras II4 | IC50 = 10.2 μg/mL | ||
| Cytotoxicty against HaCaT | IC50 = 29.8 μg/mL | ||
| F2: Cytotoxicty against HaCaT-ras A5 | IC50 = 14.6 μg/mL | ||
| Cytotoxicty against HaCaT-ras II4 | IC50 = 11.4 μg/mL | ||
| Cytotoxicty against HaCaT | IC50 = 33.2 μg/mL | ||
| F3: Cytotoxicty against HaCaT-ras A5 | IC50 = 19.1 μg/mL | ||
| Cytotoxicty against HaCaT-ras II4 | IC50 = 17.8 μg/mL | ||
| Cytotoxicty against HaCaT | IC50 = 47.3 μg/mL | ||
| F4: Cytotoxicty against HaCaT-ras A5 | IC50 = 16.2 μg/mL | ||
| Cytotoxicty against HaCaT-ras II4 | IC50 = 14.5 μg/mL | ||
| Cytotoxicty against HaCaT | IC50 = 43.4 μg/mL | ||
| Pentane (100%) fraction (F1) Pentane: diethyl ether (50:50) fraction (F2) |
F1: Cytotoxicty against HT-29 | IC50 = 22 μg/mL | [90] |
| Cytotoxicty against Caco-2 | IC50 = 18.5 μg/mL | ||
| F2: Cytotoxicty against HT-29 | IC50 = 17.5 μg/mL | ||
| Cytotoxicty against Caco-2 | IC50 = 19 μg/mL | ||
| β-2-himachalen-6-ol (HC) | Cytotoxicty against B16F-10 | IC50 = 13 μg/mL | [64] |
| Cytotoxicty against Caco2 | IC50 = 8 μg/mL | ||
| Cytotoxicty against MB-MDA-231 | IC50 = 6 μg/mL | ||
| Cytotoxicty against A549 | IC50 = 5 μg/mL | ||
| Cytotoxicty against SF-268 | IC50 = 4 μg/mL | ||
| Cytotoxicty against SW116 | IC50 = 18 and 14.5 μg/mL, 24 and 48 h respectively | [94] | |
| Cytotoxicty against HaCaT-ras II-4 | IC50 = 7 μg/mL | [93] | |
| Cytotoxicty against HaCaT-ras II-4 | IC50 = 8 μg/mL | [95] | |
| Cytotoxicty against 4T1 | IC50 = 7 μg/mL | [96] |